Trial Profile
Safety and Efficacy Study of Pl-vegf165 to Treat Diabetic Foot Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2020
Price :
$35
*
At a glance
- Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- Sponsors Human Stem Cells Institute
- 22 Feb 2017 Status changed from recruiting to completed.
- 04 Sep 2015 New trial record